Use of 2,5-dihydroxybenzene compounds and derivatives for the treatment of rosacea

A method for the treatment of rosacea, comprising administering topically to a subject in need thereof, an effective amount of a 2,5-dihydroxybenzene derivative represented by Formula (I) or a pharmaceutically acceptable salt, solvate, or isomer thereof, wherein the compound of Formula (I) is:

• wherein:
• R1 is —(CH2)aY or —CH═CH—(CH2)pZ;
• Y is —SO3H, —SO3−.X+, —SO3R3, —PO3H, —PO3−.X+, or —PO3R3, wherein when Y is —SO3H, —SO3−.X+ or —SO3R3, then R9 and R9′ are independently selected from —OH and —OR2, wherein at least one of R9 and R9′ is a substituted or unsubstituted alkylsulfonyloxy group, a substituted or unsubstituted arylsulfonyloxy group, a substituted or unsubstituted alkylcarbonyloxy group or a substituted or unsubstituted arylcarbonyloxy group;
• Z is —SO3H, —SO3−.X+, —SO3R3, —PO3H, —PO3−.X+, —PO3R3, —CO2H, —CO2−.X+ or —CO2R3;
• X+ is an organic cation or an inorganic cation, such that the general charge of the compound is neutral;
• R9 and R9′ are, independently, a substituted or unsubstituted alkylsulfonyloxy group, a substituted or unsubstituted arylsulfonyloxy group, a substituted or unsubstituted alkylcarbonyloxy group or a substituted or unsubstituted arylcarbonyloxy group;
• R2 is a substituted or unsubstituted alkyl group, a substituted or unsubstituted aryl group, a substituted or unsubstituted alkylsulfonyl group, a substituted or unsubstituted arylsulfonyl group, a substituted or unsubstituted alkylcarbonyl group or a substituted or unsubstituted arylcarbonyl group;
• R3 is a substituted or unsubstituted alkyl group or a substituted or unsubstituted aryl group;
• a is a number selected from 0, 1, 2, 3, 4, 5 and 6, provided that a is not 0 when Y is —SO3H;
• and
• p is an integer selected from 0, 1, 2, 3, 4, 5 and 6.

A method for the treatment of rosacea, comprising administering topically to a subject in need thereof, an effective amount of a 2,5-dihydroxybenzene derivative represented by Formula (I) or a pharmaceutically acceptable salt, solvate, or isomer thereof, wherein the compound of Formula (I) is:

• wherein:
• R1 is —(CH2)aY or —CH═CH—(CH2)pZ;
• Y is —SO3H, —SO3−.X+, —SO3R3, —PO3H, —PO3−.X+, or —PO3R3, wherein when Y is —SO3H, —SO3−.X+ or —SO3R3 then R9 and R9′ are independently selected from —OH and —OR2, wherein at least one of R9 and R9′ is a substituted or unsubstituted alkylsulfonyloxy group, a substituted or unsubstituted arylsulfonyloxy group, a substituted or unsubstituted alkylcarbonyloxy group or a substituted or unsubstituted arylcarbonyloxy group;
• Z is —SO3H, —SO3−.X+, —SO3R3, —PO3H, —PO3−.X+, —PO3R3, —CO2H, —CO2−.X+ or —CO2R3;
• X+ is an organic cation or an inorganic cation, such that the general charge of the compound is neutral;
• R9 and R9′ are independently selected from —OH and —OR2, wherein when R9 and R9′ are both —OR2, then said R9 and R9′ can be the same or different;
• R2 is selected from methylcarbonyl, phenylsulfonyl, 4-methylphenylsulfonyl, benzylsulfonyl, benzyl and phenyl;
• R3 is a substituted or unsubstituted alkyl group or a substituted or unsubstituted aryl group;
• a is a number selected from 0, 1, 2, 3, 4, 5 and 6, provided that a is not 0 when Y is —SO3H;
• and
• p is an integer selected from 0, 1, 2, 3, 4, 5 and 6.